Clinical Trials Logo

Clinical Trial Summary

To assess the safety and efficacy of SPD489 low-dose and high-dose treatment groups to placebo when given as adjunctive therapy to antipsychotic medication in clinically stable adults with persistent predominant negative symptoms of schizophrenia.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01234298
Study type Interventional
Source Takeda
Contact
Status Withdrawn
Phase Phase 3
Start date January 27, 2012
Completion date February 24, 2014

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05985993 - Precise Intervention Technology and Application of Low Intensity TUS on Negative Symptoms of Schizophrenia N/A
Not yet recruiting NCT06388551 - A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017 Phase 1
Completed NCT03397134 - Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia Phase 3
Recruiting NCT04620460 - Efficacy and Mechanisms of Low-intensity Focused Ultrasound on Negative Symptoms in Patients With Schizophrenia N/A